{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-039976","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.509662+00:00","generated_at":"2026-06-24T13:10:44.555664+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Therapeutics appoints Hannah Fry as Controller and CEO as principal financial officer after CFO departure","bullets":["Blaine Davis departed as CFO on July 15, 2022.","Hannah Fry appointed Controller effective July 16, 2022, with $255,000 base salary and 25,000 RSU award.","CEO Jesse Shefferman appointed as principal financial officer of the company.","Fry's severance includes six months base salary and pro-rata equity vesting on certain awards.","Fry previously served as Senior Director, Assistant Controller at Protara."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-039976","json":"https://secwatch.observer/filing/0001213900-22-039976.json","markdown":"https://secwatch.observer/filing/0001213900-22-039976.md","text":"https://secwatch.observer/filing/0001213900-22-039976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/ea162974-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T13:10:44.555664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1af188fb83","claim":"Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"left"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1f5f653e9f","claim":"Hannah Fry was appointed as Controller at Protara Therapeutics, Inc..","evidence_excerpt":"Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Controller"}],"fact_type":"executive_change"},{"claim_id":"b51a2c3bc9","claim":"Jesse Shefferman was appointed as principal financial officer at Protara Therapeutics, Inc..","evidence_excerpt":"Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}